FDA Approved Imdelltra ((tarlatamab-dlle) for Extensive Stage Small Cell Lung Cancer

Author: owner     Published: 2 months ago 0 Replies

IMDELLTRA ™ (tarlatamab-dlle) is a bispecific delta-like ligand 3 (DLL3)-directed CD3 Tcell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

This indication is approved under accelerated approval based on the overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Ref: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf

Login to Reply

Money Back Guarantee
We return Money in 24 Hours

Secure online payment
We possess SSL / Secure Certificate

12/7 customer support
Well-trained & Supportive team

PMDC Verified Doctors
Authentic & updated information


Book Online and In-clinic appointment with your doctor. Consult via Video chat and get a prescription. Ask any question in the "Forum" section and get a detailed answer. Discuss your health issues.

Connect with us

Copyright @ 2024 - All Rights Reserved Reproduction of material from any pages without permission is strictly prohibited.